Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib + ECF/X in Advanced Gastric Cancer
NCT01123473Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2010
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in gastric cancer (GC) and gastroesophageal junction adenocarcinoma comparing Lapatinib + ECF/X with Placebo + ECF/X (2 arms). Primary endpoint: Progression-Free Survival. Started Dec 2010; status: terminated.
02
Drugs
lapatinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01123473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01123473.